Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was downgraded by stock analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Tuesday. Several other research analysts have also commented on KERX. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note […]
